The purpose of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-7156 in healthy participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
66
HRS-7156, specified dose on specified day.
HRS-7156 placebo, specified dose on specified day.
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGIncidence of adverse event (AE) and serious adverse event (SAE)
Safety: Incidence of adverse event (AE) and serious adverse event (SAE).
Time frame: Up to 14 days.
Area under the concentration time curve (AUC)
Pharmacokinetics (PK) parameter of HRS-7156.
Time frame: Day 1 - Day 9.
Maximum Plasma Concentration (Cmax)
Pharmacokinetics (PK) parameter of HRS-7156.
Time frame: Day 1 - Day 9.
Time to maximum plasma concentration (Tmax)
Pharmacokinetics (PK) parameter of HRS-7156.
Time frame: Day 1 - Day 9.
Renal clearance (CLR)
Pharmacokinetics (PK) parameter of HRS-7156.
Time frame: Day 1 - Day 2.
Renin concentration of HRS-7156
Pharmacodynamics (PD) endpoint of HRS-7156.
Time frame: Day 1 - Day 9.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.